Member Info for TorquayFan

Thank you. If ? Who knows ? But thanks for the facts.
The Patented Science, will see us through. ATB

Thanks for your reply. ''Don't pay any attention'' was Inan's conclusion and I agreed with it . . .

I too do not attribute the blue week to the change in Auditors. My Sat 15.52 was just 'a read between the lines' on the change. If some sniffing is going on, any potential significant collaborator or partner, might like to know that Scancell is audited by known agent, and international status might be a factor.. We'll see. All good fun . . .

Bermuda noted on Thursday that, L & G have reduced from 18,167000 to 16,300000 . . a reduction of just under 2m shares.'' Let's hope that supply has stopped, as you noted, and maybe we can hope for some more blue !

And news of Patents and FDA approval. Have a nice day.

I'm not building a 'castle in the sky'.
As Inan says - 'don't pay any attention'. Agreed.
Just one other thought - any potential Partner for Scancell might expect a Premier League Auditor to be in charge of the unreliable backstop, that the essential 'Audit' is. . . .
A quiet word in the right place and a change - is how it's done. Via tender of course.
So it might be that some sniffing is going on. I hope so.

I'm not flying any kites - just musing.

''Champion Accountants LLP ("Champion") . . . did not participate in the tender'' . . . That was surprising to me as smaller Audit firms are usually scrambling for Clients - it's the way that they grow their business. Champion acknowledged that nothing is amiss so, ever hopeful - I wonder if they know Scancell is moving up a gear and out of their orbit ?

Otherwise this is just routine stuff - BDO and Eversheds look a competent team. Nice weekend all.

Well it's possible that the incumbents couldn't cope with Scancell's future so have opted out - who knows ? Krafty it's good to read your comment - this change might mean a lot or next to 'nowt.

The only way is up ! Hopefully. All being well.

''Keytruda gets okay from FDA for adjuvant melanoma - February 20, 2019.

The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes. It’s the first time that PD-1 inhibitor Keytruda (pembrolizumab) has been approved in the US for adjuvant use in any cancer, although Merck picked up European approval for this indication in December.''

https://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/?

Thanks for the data about the 'Clinical Hold' - good news on this front would be welcome indeed. ATB

Crumbs thanks for some excellent posts yesterday - great stuff and Ray P too.
This GEM in your 09.48 nearly cheered me up !!

Immunologist James P Allision.... 2019

''From my viewpoint, there are two types of resistance to immune checkpoint inhibitors,” explains Allison. One is innate resistance in some patients causing failure to respond, which can be overcome, in part, by combining multiple checkpoints or with chemotherapy, radiation, or other approaches. But there are also patients who do not respond because they have acquired defects in gamma-interferon (IFN?) or beta-2-microglobulin (B2M) signaling, thus losing the ability to respond to the lytic events of IFN? or the ability to present tumor antigens to immune cells, he says. “I think there are ways around that, involving the development of CD4-TARGETED AGENTS, particularly using VACCINES” he notes.''

Exciting thoughts that bear repeating - and from the horse's mouth. Thanks to James P Allison . . . .

Hi Tommy. Yes. Berm has now acknowledged that. (Just passing it on). Well done. ATB

has noted this . .

''Have just caught up on lse bb. re. Tomyflowers 6.57 glassdoor Ichor post early this morning. Might be worth someone pointing out that the company being reviewed in his link isn't Ichor Medical Systems - it's Ichor Systems, a completely different company and no connection at all to Ichor MS.''

Just passing it on - dinner time. GLA

Crumbs - I just wanna blame Donald Trump anyway. Maybe news next week ? GLA

Tommy / Crumbs - whatever the hold up is with the FDA, we will probably never know.

I suggest, right or wrong, we all agree to blame Donald Trump and his shutdown !!

GLA

It's confirmed there is to be no further US Govt. shutdown.

So FDA. skates on for Scancell please !

Apologies if this has been linked before - a lorra lorra money around I-O atm :-

''GlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an immuno-oncology drug that made a splash at last year’s ESMO meeting. The global alliance gets off the ground with a 300 million euro payment to Merck from GSK to secure co-development and co-marketing rights to the bifunctional fusion protein immunotherapy, an anti-PD-L1/TGF beta trap in clinical trials for solid tumours including non-small cell lung cancer (NSCLC).

The deal includes another €500 million tied to a lung cancer programme and €2.9 billion in additional development and commercial milestones that takes the totally tally to a hefty €3.7 billion (around $4.2bn).''

https://pharmaphorum.com/top-stories/gsk-bolts-on-immuno-oncology-candidate-with-e3-7bn-merck-deal/?

Sorry C7 but this is a 'Public' forum and I'll post when I feel I need to. ATB

Commiserations - I could not quite believe my eyes this morning when I saw your result.
A CFC 4th place looks a long way off right now.

Regarding the 'H' word, I've already explained the reason for my comments.

Chin up - the CFC result hasn't worsened Scancell's prospects - it just feels that way !

Yes I ignored your post. Good advice.

OK. That worked well ? ATB

Berm - ''a very comprehensive review 'Turning the corner on therapeutic cancer vaccines' was published today by Nature's npj vaccines journal. The author is Robert Hollingsworth, CSO and VP of Pfizer's cancer vaccines Division so also perhaps an insight into the thinking of big pharma.''

Here's a paragraph from the 'Conclusion' - I didn't get the bit in the middle LOL. (Just the 'Intro' and 'Outro').
Feb 2019.

''Therapeutic cancer vaccines offer an attractive alternative immunotherapy because of their potential safety, specificity, and long-lasting response—perhaps even cures—due to stimulation of immune memory. Unfortunately, many previous attempts to develop effective therapeutic cancer vaccines yielded disappointing results. Lessons learned from these failed attempts are now allowing cancer vaccine research to turn the corner and begin to achieve some promising clinical results.''

https://www.nature.com/articles/s41541-019-0103-y#Sec2

I've moved on NOW until poked again. ATB